Published On: Wed, Oct 19th, 2016

Inotek Pharmaceuticals Corporation (ITEK) Analyst Review


A number of investment brokers have recently updated their price targets on shares of Inotek Pharmaceuticals Corporation (ITEK).

Most recent broker ratings

09/20/2016 – H.C. Wainwright began new coverage on Inotek Pharmaceuticals Corporation giving the company a “buy” rating. They now have a USD 22 price target on the stock.

11/16/2015 – Inotek Pharmaceuticals Corporation had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 29 price target on the stock.

07/24/2015 – Inotek Pharmaceuticals Corporation had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 30 price target on the stock.

07/23/2015 – Inotek Pharmaceuticals Corporation had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 40 price target on the stock.

07/23/2015 – Inotek Pharmaceuticals Corporation had its “buy” rating reiterated by analysts at Nomura. They now have a USD 30 price target on the stock.

The share price of Inotek Pharmaceuticals Corporation (ITEK) was down -0.63% during the last day of trading, with a day high of 8.05. 94142 shares were traded during the last session.

The stock’s 50 day moving average is 8.23 and its 200 day moving average is 8.34. The stock’s market capitalization is 212.75M. Inotek Pharmaceuticals Corporation has a 52-week low of 5.81 and a 52-week high of 13.36.

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.